Pharma companies News

Now we will show you the DNA Investigation Report of the loot of MRP of pharmaceutical companies. And will tell you how India's Pharma Lobby is earning black money by ignoring the orders and rules of the Government of India.

During a visit to Jan Aushadhi Kendra in Dehradun, the health minister stressed that the issue of medicines is definitely linked with public health.

The first case of Omicron was reported in South Africa on 24 November but the world came to know about this new variant only in the first week of December. Well, the atmosphere of fear created by this made the vaccine companies rich.

GlaxoSmithKline Pharmaceuticals on Saturday reported 32.91 percent decline in net profit at Rs 52.95 crore for the quarter ended December 31, on account of mandatory price cuts as well as demonetisation.

The government has moved Supreme Court challenging the Delhi high court order scrapping ban on popular drugs(fixed-dose-combination drugs)such as Corex, Saridon and Vicks Action 500, D Cold Total, Ascoril-C, and many more in December.

 Pharma companies are likely to report sequentially flat EBITDA growth in 3QFY17, impacted by pricing pressure and higher R&D expenditure, a report said.

The Indian pharmaceutical companies exhibit strong business profiles underpinned by good products and geographic diversity as compared to some global peers, American rating agency Moody`s said on Friday.

Delhi High Court on Monday stayed the ban on some fixed dose combination (FDC) drugs of Glaxo SmithKline, Wockhardt and Laboratories Griffon.

For drugs priced between Rs 20-50, the panel has proposal to cap the margin at 40 percent.

Delhi High Court today told the government not to take any coercive action against pharma companies, including Novartis India Limited and Cipla Ltd, in connection with the notices issued to them for allegedly not ensuring implementation of the revised drug pricing of 2013.

Continued strength in the dollar when the Federal Reserve raises interest rates will also boost their income. More than 40 percent of over-the-counter and generic prescription drugs sold in the United States come from India.

India's business loss arising from the European Union's ban on 700 generic drugs is likely to be around USD 1.2 billion, says industry body Pharmexcil.

The Mumbai-based drug major, which acquired Ranbaxy in a USD 4 billion deal, feels it is important for the merged entity to "re-establish" the trust between Ranbaxy and the US Food and Drug Administration (USFDA).

Slamming the practice of pharma companies offering freebies and gifts to doctors, government auditor CAG said that drug makers have claimed tax benefits on such expenses despite these being prohibited by law.

With just 41 out of top 100 pharma firms responding to its direction to register for online database, drug price regulator NPPA has warned to take action if the rest of the companies did not comply with its order immediately.

The early termination of the waiting period under the HSR Act satisfies one of the essential conditions to the closing of the Ranbaxy acquisition, it added.

It's been a year of bitter medicine for Indian pharma companies with fines worth millions of dollars imposed by various foreign regulators, even as they stitched together deals worth billions of dollars, including the high profile Sun-Ranbaxy merger.

While approving their USD 4-billion merger, Competition Commission of India (CCI) has asked the two companies to divest seven products to address anti-competitive concerns.

India's pharmaceuticals industry accounts for about 2.4 percent of the global pharma industry by value and 10 percent by volume.

This is probably the first instance where the CCI has ordered a public scrutiny of a proposed merger and acquisition (M&A) deal to ensure compliance to fair trade regulations.